KUALA LUMPUR, March 23 — Malaysia’s Ministry of Health (MOH) has assured the public that the country’s supply of medicines remains stable and under control, despite ongoing conflict in the Middle East.
According to the ministry, current assessments indicate that any short-term impact from the conflict is minimal. Medicine stocks at MOH healthcare facilities are maintained at levels sufficient for one to three months of usage, supported by an additional buffer stock of up to two months held by concession companies responsible for logistics supply.
Overall, the supply of medicines nationwide continues to be closely monitored through existing mechanisms. This includes a supply disruption reporting system managed by the National Pharmaceutical Regulatory Agency (NPRA), where Product Registration Holders (PRH) are required to report any issues. As of March 22, 2026, no increase in reported supply disruptions has been detected.
Feedback from the local pharmaceutical industry indicates that domestic manufacturers currently hold raw material stocks for up to three months and finished products for approximately two months. Importers are also actively monitoring their respective supply chains to ensure continuity.
The Ministry of Health stated it will continue to closely observe developments in the Middle East and remains committed to taking proactive measures. These include establishing a dedicated task force comprising pharmaceutical industry players and relevant stakeholders to ensure continued access to essential medicines, particularly those listed under Malaysia’s National Essential Medicines List (NEML).
